{
    "clinical_study": {
        "@rank": "6676", 
        "arm_group": [
            {
                "arm_group_label": "Treatment", 
                "arm_group_type": "Experimental", 
                "description": "Treatment, 2.5 mg Chlorhexidine Gluconate chip (PerioChip\u00ae) inserted every two weeks starting at Baseline for the first 3 months, plus mechanical Subgingival Debridement at Baseline and 3 months."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "Mechanical Subgingival Debridement at Baseline and 3 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of the study is to assess the efficacy and safety of PerioChip\u00ae (Chlorhexidine\n      gluconate chip) in the treatment of patients with Peri-implantitis.\n\n      The hypothesis of the study is that PerioChip\u00ae in adjunct to mechanical subgingival\n      debridement is more effective in the treatment of peri-implantitis when compared to the\n      common method of mechanical subgingival debridement alone. The primary efficacy measure will\n      be the reduction in probing pocket depth at 6 months as measured at sites of qualifying\n      target implant."
        }, 
        "brief_title": "The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip\u00ae) in Therapy of Peri-implantitis", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Peri-Implantitis", 
        "condition_browse": {
            "mesh_term": "Peri-Implantitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Good general health\n\n          -  At least one implant in the oral cavity with clinical and radiographical signs of\n             peri-implantitis. Including bone loss in combination with bleeding and/or suppuration\n             on probing and a peri-implant Probing Depth (PD) of 5-8 mm.\n\n          -  The implants have been in function for more than 2 years.\n\n          -  Fixed prosthetic restoration of the implant.\n\n        Exclusion Criteria:\n\n          -  Pregnancy.\n\n          -  Patient uses Chlorhexidine oral rinses/ mouthwashes on a regular basis.\n\n          -  Allergic reaction to Chlorhexidine.\n\n          -  Active Periodontitis which required definitive treatment.\n\n          -  Presence of orthodontic appliances, or any removable appliances, that impinges on\n             the tissues being assessed.\n\n          -  Use of systemic antibiotic therapy and/or chronically use of non-steroidal\n             anti-inflammatory drugs (NSAIDs).\n\n          -  Uncontrolled diabetes, of any type."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02080403", 
            "org_study_id": "CLI/016P"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip\u00ae will be inserted in each one of the target implant.", 
            "intervention_name": "2.5 mg Chlorhexidine gluconate chip", 
            "intervention_type": "Drug", 
            "other_name": "PerioChip\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Chlorhexidine gluconate", 
                "Anti-Infective Agents", 
                "Chlorhexidine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Peri-Implantitis", 
            "Periodontal Diseases", 
            "Chlorhexidine gluconate", 
            "PerioChip", 
            "Anti-Infective Agents", 
            "Mouth Diseases", 
            "Antiseptics"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Haifa", 
                    "country": "Israel", 
                    "zip": "9602"
                }, 
                "name": "Department of Periodontology, School of Graduate Dentistry, Rambam Health Care Center"
            }, 
            "investigator": {
                "last_name": "Eli Machtei, Prof.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "Multi-Center Phase 3 Trial of Chlorhexidine Gluconate Chip for the Use in Subjects With Peri-Implantitis.", 
        "overall_contact": {
            "email": "sigalit.melcer@dexcel.com", 
            "last_name": "Sigalit Melcer"
        }, 
        "overall_official": {
            "affiliation": "Department of Periodontology, School of Graduate Dentistry, Rambam Health Care Center Haifa, Israel, 9602", 
            "last_name": "Eli Machtei, Prof.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United Kingdom: National Health Service", 
                "Israel: Ethics Commission"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Absolute change in mean probing Pocket Depth for selected target implants", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02080403"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Absolute change in mean probing Pocket Depth of selected target implants in patients with baseline Pocket Depth measurement of 6-8 mm inclusive", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 months"
            }, 
            {
                "measure": "Change in percentage of selected target implants Bleeding on Probing", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 4 and 6 months"
            }, 
            {
                "measure": "Absolute change in mean probing Pocket Depth of selected target implants", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 4 months"
            }
        ], 
        "source": "Dexcel Pharma Technologies Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dexcel Pharma Technologies Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}